Soft tissue sarcomas of adults: State of the translational science Journal Article
| Authors: | Borden, E. C.; Baker, L. H.; Bell, R. S.; Bramwell, V.; Demetri, G. D.; Eisenberg, B. L.; Fletcher, C. D. M.; Fletcher, J. A.; Ladanyi, M.; Meltzer, P.; O'Sullivan, B.; Parkinson, D. R.; Pisters, P. W. T.; Saxman, S.; Singer, S.; Sundaram, M.; Van Oosterom, A. T.; Verweij, J.; Waalen, J.; Weiss, S. W.; Brennan, M. F. |
| Article Title: | Soft tissue sarcomas of adults: State of the translational science |
| Abstract: | Sarcomas - like leukemias, which are also mesodermal malignancies - carry biological significance disproportionate to their clinical frequency. Identification of mutations and translocations associated with these tumors has illuminated aberrant signaling pathways that cause these diseases, determine their behavior, and are therapeutic targets. Activated receptor-associated tyrosine kinase c-kit, mutated in most gastrointestinal stromal tumors, has proven a clinically effective target for enzyme inhibition. A translocation involving a single gene family, consisting of EWS and related genes, has been identified in five different sarcomas, and its chimeric protein products could prove similarly amenable to inhibitors. Resolution of the histopathological complexity is being aided by data from molecular and chromosomal characterization. Improvements in imaging, definition of prognostic factors, and surgical and radiotherapeutic treatment have resulted in improved local control. Continued progress will depend on further adapting the rapidly evolving technologies of genomics and proteomics. It will also depend upon accurate histopathological diagnosis based on validated reagents and consistent methodologies applied to adequate tissue samples derived from patients with complete clinical data. Finally, multicenter, coordinated trials, such as those that occurred with assessment of imatinib mesylate in metastatic gastrointestinal stromal tumors, will assure the most rapid reductions in morbidity and mortality. |
| Keywords: | signal transduction; adult; cancer survival; treatment outcome; leukemia; unclassified drug; gene mutation; major clinical study; clinical trial; histopathology; review; doxorubicin; cancer combination chemotherapy; validation process; drug targeting; cancer radiotherapy; chemotherapy, adjuvant; drug megadose; nuclear magnetic resonance imaging; positron emission tomography; methodology; diagnostic accuracy; gastrointestinal stromal tumor; imatinib; stem cell factor receptor; edema; metastasis; drug eruption; enzyme inhibition; leukopenia; nausea; vomiting; gene product; chronic myeloid leukemia; cancer mortality; ifosfamide; sarcoma; chimera; drug fatality; oligonucleotide array sequence analysis; gene identification; fluorodeoxyglucose f 18; tyrosine kinase receptor; soft tissue sarcoma; epirubicin; chromosome translocation; retroperitoneal neoplasms; dna microarray; chromosome aberrations; anthracycline derivative; karyotype; karyotyping; mesoderm; meta analysis; multigene family; phosphatidylinositol 3 kinase inhibitor; abdominal bleeding; humans; human; priority journal; ly 29004 |
| Journal Title: | Clinical Cancer Research |
| Volume: | 9 |
| Issue: | 6 |
| ISSN: | 1078-0432 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2003-06-01 |
| Start Page: | 1941 |
| End Page: | 1956 |
| Language: | English |
| PUBMED: | 12796356 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Export Date: 25 September 2014 -- Source: Scopus |
Citation Impact
Related MSK Work